New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
07:33 EDTGWPHCNN documentary could be catalyst for GW Pharmaceuticals, says Piper
Piper Jaffray believes CNN's second documentary tomorrow night on the medicinal properties of the cannabis plant could be a positive catalyst for shares of GW Pharmaceuticals. Piper notes CNN's Sanjay Gupta speaks with GW. The firm believes the show could move GW further into the medical marijuana national spotlight and it keeps an Overweight rating on the stock with a $97 price target.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
18:20 EDTGWPHOn The Fly: After Hours Movers
Subscribe for More Information
17:26 EDTGWPHGW Pharmaceuticals CEO says market for Epidiolex may be expanded over time
Subscribe for More Information
14:55 EDTGWPHGW Pharma analyst day positive, reason for sell-off unclear, says Piper Jaffray
Subscribe for More Information
08:07 EDTGWPHGW Pharmaceuticals data should 'silence the doubters,' says Piper Jaffray
Subscribe for More Information
07:15 EDTGWPHGW Pharmaceuticals says Epidiolex physician reports show signals of efficacy
Subscribe for More Information
07:11 EDTGWPHGW Pharmaceuticals announces preliminary topline results of Phase 2a trial
Subscribe for More Information
06:38 EDTGWPHGW Pharmaceuticals to host research and development day
Subscribe for More Information
October 8, 2014
11:23 EDTGWPHGW Pharmaceuticals slides after U.K. body recommends against use of Sativex
Subscribe for More Information
10:24 EDTGWPHGW Pharmaceuticals weakness on NICE guidance 'irrational,' says Piper Jaffray
Subscribe for More Information
10:04 EDTGWPHNICE guidance does not recommend use of Sativex in MS care
In an update to its original 2003 guideline, the U.K.'s National Institute for Health and Care Excellence has set out how people with multiple sclerosis, or MS, can receive better care. In the update, NICE recommends that people with suspected MS should be referred to a consultant neurologist. MS should not be diagnosed on the basis of MRI findings alone and only a consultant neurologist should make the diagnosis of MS. The guidance does not recommend the use of the cannabinoid drug Sativex, manufactured by GW Pharmaceuticals (GWPH), or fampridine as they provide only a modest benefit at a significant cost to the NHS, NICE stated. Shares of GW Pharmaceuticals are down 7% in early trading following the publication of NICE's new guidelines.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use